These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22122184)

  • 61. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S; Ibayashi S; Matsumoto M; Nagao T; Nagata K; Nakagawara J; Tanahashi N; Tanaka K; Toyoda K; Yasaka M
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].
    Gassanov N; Caglayan E; Erdmann E; Er F
    Dtsch Med Wochenschr; 2010 Feb; 135(6):256-9. PubMed ID: 20104442
    [No Abstract]   [Full Text] [Related]  

  • 63. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
    Stangier J; Stähle H; Rathgen K; Roth W; Shakeri-Nejad K
    J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 66. First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR.
    Thompson CA
    Am J Health Syst Pharm; 2010 Dec; 67(23):1974, 1976. PubMed ID: 21098360
    [No Abstract]   [Full Text] [Related]  

  • 67. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.
    Rosencher N; Albaladejo P
    Expert Opin Pharmacother; 2012 Feb; 13(2):217-26. PubMed ID: 22192174
    [TBL] [Abstract][Full Text] [Related]  

  • 68. S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.
    Rupin A; Marx I; Vallez MO; Mennecier P; Gloanec P; De Nanteuil G; Verbeuren TJ
    J Thromb Haemost; 2011 Jul; 9(7):1375-82. PubMed ID: 21481181
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [New oral anticoagulants: prospects].
    Fiessinger JN
    Rev Prat; 2010 May; 60(5):613-6. PubMed ID: 20564841
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dabigatran etexilate: management in acute ischemic stroke.
    Javedani PP; Horowitz BZ; Clark WM; Lutsep HL
    Am J Crit Care; 2013 Mar; 22(2):169-76. PubMed ID: 23455868
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate.
    Hussar DA; Zimmerman DE
    J Am Pharm Assoc (2003); 2011; 51(1):122-6. PubMed ID: 21247838
    [No Abstract]   [Full Text] [Related]  

  • 72. Dabigatran etexilate: what do hospitalists need to know?
    Zeidan A; Faltas B; Streiff M
    J Hosp Med; 2012 Mar; 7(3):262-9. PubMed ID: 22128108
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New therapeutic option for thromboembolism--dabigatran etexilate.
    Nishio H; Ieko M; Nakabayashi T
    Expert Opin Pharmacother; 2008 Oct; 9(14):2509-17. PubMed ID: 18778188
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The new anticoagulants.
    Stone WM; Tonnessen BH; Money SR
    Perspect Vasc Surg Endovasc Ther; 2007 Sep; 19(3):332-5. PubMed ID: 17911567
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials.
    Eriksson BI; Smith JJ; Caprini J; Hantel S; Clemens A; Feuring M; Schnee J; Barsness GW
    Thromb Res; 2012 Sep; 130(3):396-402. PubMed ID: 22704461
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Thromboembolism in a patient with a mechanical mitral valve during anticoagulation with dabigatran etexilate.
    Kuwauchi S; Watanabe S; Abe K; Yamasaki M; Ito J; Kawazoe K
    Ann Thorac Surg; 2013 Nov; 96(5):1863-4. PubMed ID: 24182477
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New anticoagulant agents: direct thrombin inhibitors.
    Nutescu EA; Shapiro NL; Chevalier A
    Cardiol Clin; 2008 May; 26(2):169-87, v-vi. PubMed ID: 18406993
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
    Stangier J
    Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Direct thrombin inhibitors.
    Di Nisio M; Middeldorp S; Büller HR
    N Engl J Med; 2005 Sep; 353(10):1028-40. PubMed ID: 16148288
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.